Most (10/11) cancer mutations tested did not affect ESR1 binding to the cancer promoters tested, suggesting that these mutations, if functional, likely affect other ESR1 molecular functions such as interactions with other TFs and cofactors. This evidence concerns the gene ESR1 and cancer.